埃博拉出血热疫苗研究进展

Research Progress on Ebola Hemorrhagic Fever Vaccine

埃博拉出血热(Ebola Hemorrhagic Fever,EHF)是一种烈性的传染病,病死率很高,最高可达90%。EHF自1976年首次在前扎伊尔和苏丹发生流行至今,共发生人间较大规模流行6次,暴发、流行或散发病例多次。据WHO统计从1976年至今,已有2000多确诊病例,1300多人死于不同亚型的EHF。虽然目前还没有特效的抗病毒药物和有效的疫苗可用于人体预防和治疗EHF,但近年来国际上在疫苗的研究方面取得了较大的进展。本文对EHF疫苗的相关研究进展进行综述。

Ebola hemorrhagic fever（Ebola Hemorrhagic Fever,EHF） is a severe infectious disease,with its high fatality rate up to 90%.EHF happened in the former Zaire and the Sudan epidemic first in 1976,since then larger-scale epidemics in human have occurred for 6 times,with outbreaks,epidemics or sporadic cases several times.According to the statistics of WHO,from 1976 to the present,there were more than 2 000 confirmed cases,and more than 1 300 cases died of different subtypes of EHF.Although no effects of antiviral drugs and effective vaccines were available for prevention and treatment for EHF,research on vaccine had made great progress internationally in recent years.In this paper,the related research progress of EHF vaccine was reviewed.